Reclaiming Asia’s Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
The European Chamber of Commerce in Korea (ECCK) is the pre-eminent association of European companies conducting business in or related to Korea. Representing the common voice of the European business community in Korea, the ECCK aims to function as the platform for information exchange, effective communication channel to the Korean authorities and convenor of networking opportunities for European businesses. The ECCK is a non-profit and non-political organisation.
The ECCK was officially founded on 3 December 2012, upon the approval of the Ministry of Knowledge Economy (Ministry of Trade, Industry and Energy as of 2013). With its clear legal status defined under Korea’s Chamber of Commerce and Industry Act of 2008, the ECCK has focused on transparency and co-operation as its fundamental values.
The ECCK maintains its open door policy of actively listening to members’ opinions and suggestions in developing its programmes and activities. The ECCK seeks for collaboration with national chambers of commerce and European business associations to identify issues of common concern and effectively represent the interests of the European business community.
The ECCK is a strong believer in mutual prosperity. The ECCK hopes to contribute to fostering an optimal business climate for both European and local Korean companies. Moreover, as a good corporate citizen, the ECCK is determined to develop and carry out activities for the benefit of the Korean society.
The organisation is governed by the Board of Directors, entrusted with members’ mandate. The Advisory Board, comprised of national chambers and embassies, provides guidance and advice in regard to direction and activities. The Secretariat manages daily operation and activities of the Chamber.
Address
5F, Seoul Square, 416 Hangang-daero, Jung-gu,
Seoul 100-714, Korea
서울특별시중구한강대로 416 서울스퀘어 5층
(우 100-714)
Tel +82 2 6261 2700
Fax +82 2 6261 2730
E-mail ecck@ecck.eu
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
